

MERGER ANNOUNCEMENT M/24/010 – EXPONENT / CHANELLE HOLDCO 3 LIMITED

Section 21 of the Competition Act 2002

Competition and Consumer Protection Commission clears the proposed acquisition by Exponent, through its subsidiary Herriot Pharma Bidco Limited, of sole control of Chanelle HoldCo 3 Limited

29 February 2024

The Competition and Consumer Protection Commission has today cleared the proposed transaction whereby Exponent Private Equity LLP (“Exponent”), through its subsidiary Herriot Pharma Bidco Limited will acquire sole control of Chanelle HoldCo 3 Limited. The proposed transaction was notified under the Competition Act 2002, as amended, on 13 February 2024.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Additional Information

Exponent Private Equity LLP is an international private equity group based in the United Kingdom which makes investments in businesses in the State, the UK and across Europe.

Herriot Pharma Bidco Limited is a limited liability company. Herriot Pharma Bidco Limited is a subsidiary of Exponent Private Equity LLP.

Chanelle HoldCo 3 Limited is a direct subsidiary of Chanelle Pharma Limited. Chanelle HoldCo 3 Limited specialises in the development, registration, manufacture, wholesale, distribution, out-license, commercialisation and supply of both human and veterinary generic pharmaceutical products.